Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy.
about
Dilated Cardiomyopathy: Phosphorus 31 MR Spectroscopy at 7 T.Imaging myocardial metabolic remodeling.Adiabatic excitation for 31 P MR spectroscopy in the human heart at 7 T: A feasibility study.Proteomic analysis of mitochondria reveals a metabolic switch from fatty acid oxidation to glycolysis in the failing heart.Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts.In vivo magnetic resonance methods in pharmaceutical research: current status and perspectives.Progressive loss of creatine maintains a near normal DeltaG approximately (ATP) in transgenic mouse hearts with cardiomyopathy caused by overexpressing Gsalpha.ATP flux through creatine kinase in the normal, stressed, and failing human heart.Reduced in vivo high-energy phosphates precede adriamycin-induced cardiac dysfunction.Advances in human cardiac 31P-MR spectroscopy: SLOOP and clinical applications.Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts.Impaired ATP kinetics in failing in vivo mouse heart.Cardiovascular nuclear magnetic resonance: basic and clinical applications.Metabolic rates of ATP transfer through creatine kinase (CK Flux) predict clinical heart failure events and death.Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium.In vivo mouse myocardial (31)P MRS using three-dimensional image-selected in vivo spectroscopy (3D ISIS): technical considerations and biochemical validations.Transmurally differentiated measurement of ATP hydrolysis rates in the in vivo porcine hearts.PGC-1alpha and ERRalpha target gene downregulation is a signature of the failing human heart.Abnormal energetics and ATP depletion in pressure-overload mouse hearts: in vivo high-energy phosphate concentration measures by noninvasive magnetic resonance.Reduced myocardial creatine kinase flux in human myocardial infarction: an in vivo phosphorus magnetic resonance spectroscopy study.Quantification of human high-energy phosphate metabolite concentrations at 3 T with partial volume and sensitivity corrections.Potential of metabolic agents as adjunct therapies in heart failure.Highly-accelerated quantitative 2D and 3D localized spectroscopy with linear algebraic modeling (SLAM) and sensitivity encoding.Expert consensus document: Mitochondrial function as a therapeutic target in heart failure31P magnetic resonance spectroscopy of the Sherpa heart: a phosphocreatine/adenosine triphosphate signature of metabolic defense against hypobaric hypoxia.Energetics and metabolism in the failing heart: important but poorly understood.Metabolic remodelling in human heart failure.PET imaging of cardiac hypoxia: opportunities and challenges.Creatine phosphate: pharmacological and clinical perspectives.Mechanisms of disease: is mitochondrial function altered in heart failure?MRS: a noninvasive window into cardiac metabolism.Principals and clinical applications of magnetic resonance cardiac spectroscopy in heart failure.A comprehensive review of the bioenergetics of fatty acid and glucose metabolism in the healthy and failing heart in nondiabetic condition.Creatine kinase-mediated improvement of function in failing mouse hearts provides causal evidence the failing heart is energy starved.Accurate phosphorus metabolite images of the human heart by 3D acquisition-weighted CSI.Decline of contractility during ischemia-reperfusion injury: actin glutathionylation and its effect on allosteric interaction with tropomyosin.Substrate-specific impairment of mitochondrial respiration in permeabilized fibers from patients with coronary heart disease versus valvular disease.Assessing tissue metabolism by phosphorous-31 magnetic resonance spectroscopy and imaging: a methodology review.Mitochondrial Transplantation in Myocardial Ischemia and Reperfusion Injury.Diabetic db/db mice do not develop heart failure upon pressure overload: a longitudinal in vivo PET, MRI, and MRS study on cardiac metabolic, structural, and functional adaptations.
P2860
Q30355877-40EB2A87-0521-40F6-BA07-30316B30BDF8Q30464469-C02687FF-35F0-46AD-9606-22FEC97A149CQ30490553-B1939215-1FAB-4E82-AF30-8EC54D8A3450Q30915732-CFFCB03A-E438-4E9C-9E7E-9F8B5763295EQ31007181-AC5A7E52-A770-4C8B-9804-C9D61C129121Q33678501-08EF4457-89A0-4590-81E5-D4CA519E3F33Q33724552-47EAD9C9-A711-41BF-9E21-3E209BD441FEQ33756653-6CE10644-598F-47A7-AAB2-77DB21E6DD50Q34092826-73676D67-53B5-4169-A4AB-20D5F8A4B8C7Q34199589-BEAFA171-F243-44C1-BB16-BAE3EE9A6FE7Q34398552-5B7B4DCD-9FF3-4167-BE4E-7F4547672EA6Q34732421-279A0DF4-42A6-4F48-81A8-B31E7FEA51B1Q35019517-448BA45F-379C-4EE5-B399-312C8A9D2ED3Q35633752-8FF15642-6909-48FE-8393-CA6C748463A7Q35659510-7D80249D-29F3-4C0A-9B66-F0DC052460A0Q36070598-F655064D-69F8-4AEF-BFF0-626770B91796Q36803252-C74BA4B0-3CE7-4E41-801D-642C335FB47BQ37189947-08182748-F909-4724-9FC4-2296016039FBQ37264406-94B481AC-5D66-4100-A86D-BDA55C9C301FQ37345272-10F95AAC-509A-425B-BCFF-1AF825F4947FQ37588561-9E6E8A51-4AAB-4889-A8C1-45C83C027B9CQ37608595-7E363F89-68F8-4DBF-B74E-59EA25A3F746Q37685555-3D0FC45E-D4A4-4530-AFCC-56AB7E4978FDQ37699474-A3752020-5EAB-4D7E-AABD-67072E5278AAQ37734761-113C0F5B-31E5-4FF2-A8AA-1A8983DBAE33Q37746834-8B038534-6360-4AB0-BCB0-411BD04F0C2CQ37849446-DBF718F6-7AAB-4D00-8292-98B346576B15Q37904019-ACC1C800-0F3A-4780-95F9-07B3504C23D2Q37980661-4BE6B9DA-36DA-40E7-8B0D-AE4CDCA5D23EQ38091973-CDDA7548-024B-466E-BE48-358DC9239AAEQ38502630-3558D8CB-AEB4-41FF-B5FA-7E79CFE23AC3Q39225754-AC5775DC-A0E2-4E00-B180-E3A3197684B8Q39325799-32244D20-DCFE-4376-B693-E466BACB1B69Q40053312-7A5268CA-FEDC-4529-9001-22DFFC6BA84EQ43589403-8D0642D4-E205-4BF8-BF86-9299BECC285AQ46776183-5A80CE2A-FC45-4B15-A335-82A20B2BE122Q46813026-1D6A946F-41E3-48DB-BFDA-2C7B698BB756Q47191918-47FEC5F0-F994-4AFD-A9C1-6460F99C88E1Q47291629-DDCA3A32-F76A-4BAE-B931-48FB94064304Q50861790-69DEB47D-75F5-46A6-997F-911FE1628EB6
P2860
Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy.
description
1991 nî lūn-bûn
@nan
1991 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Altered myocardial high-energy ...... s with dilated cardiomyopathy.
@ast
Altered myocardial high-energy ...... s with dilated cardiomyopathy.
@en
Altered myocardial high-energy ...... s with dilated cardiomyopathy.
@nl
type
label
Altered myocardial high-energy ...... s with dilated cardiomyopathy.
@ast
Altered myocardial high-energy ...... s with dilated cardiomyopathy.
@en
Altered myocardial high-energy ...... s with dilated cardiomyopathy.
@nl
prefLabel
Altered myocardial high-energy ...... s with dilated cardiomyopathy.
@ast
Altered myocardial high-energy ...... s with dilated cardiomyopathy.
@en
Altered myocardial high-energy ...... s with dilated cardiomyopathy.
@nl
P2093
P1476
Altered myocardial high-energy ...... s with dilated cardiomyopathy.
@en
P2093
Bottomley PA
Gerstenblith G
P304
P356
10.1016/0002-8703(91)90527-O
P407
P433
P577
1991-09-01T00:00:00Z